Could less be more? study tests cutting biologic doses for Crohn's and colitis

This study is testing whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of the biologic drug ustekinumab. Participants will either switch from injections every 4 weeks to every 8 weeks, or from every 8 weeks to every 12 weeks. Researchers will monitor blood levels, inflammation markers, and gut health to see if remission holds. The goal is to find out if lower doses can still keep the disease under control.